{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T08:25:38Z","timestamp":1748075138522},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,24]]},"DOI":"10.7759\/cureus.8805","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T17:48:12Z","timestamp":1593020892000},"source":"Crossref","is-referenced-by-count":2,"title":["Dapsone in the Management of Pemphigus and Pemphigoid: Rediscovery of its Long-Lost Efficacy"],"prefix":"10.7759","author":[{"given":"Salim","family":"Alkeraye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama R","family":"AlZamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suha","family":"Alenazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto D","year":"2019","unstructured":"Miyamoto D, Giuli Santi C, Aoki V, Wakisaka Maruta C. Bullous pemphigoid. An Bras Dermatol. 2019, 94:133-146. 10.1590\/abd1806-4841.20199007","journal-title":"An Bras Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the european dermatology forum consensus in collaboration with the european academy of dermatology and venereology","volume":"172","author":"Feliciani C","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, et al.. Management of bullous pemphigoid: the european dermatology forum consensus in collaboration with the european academy of dermatology and venereology. Br J Dermatol. 2015, 172:867-877. 10.1111\/bjd.13717","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age","volume":"138","author":"Rzany B","year":"2002","unstructured":"Rzany B, Partscht K, Jung M, et al.. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002, 138:903-908. 10.1001\/archderm.138.7.903","journal-title":"Arch Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.3.350","article-title":"Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations","volume":"284","author":"Yancey KB","year":"2000","unstructured":"Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA. 2000, 284:350-356. 10.1001\/jama.284.3.350","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly P","year":"2011","unstructured":"Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011, 29:432-436. 10.1016\/j.clindermatol.2011.01.013","journal-title":"Clin Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro A","year":"2019","unstructured":"Porro A, Seque C, Ferreira M, Enokihara M. Pemphigus vulgaris. An Bras Dermatol. 2019, 94:264-278. 10.1590\/abd1806-4841.20199011","journal-title":"An Bras Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15930","article-title":"British association of dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman KE","year":"2017","unstructured":"Harman KE, Brown D, Exton LS, et al.. British association of dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017, 177:1170-1201. 10.1111\/bjd.15930","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly P","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017, 389:2031-2040. 10.1016\/S0140-6736(17)30070-3","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01090","article-title":"High-dose intravenous immunoglobulin in skin autoimmune disease","volume":"10","author":"Hoffmann JHO","year":"2019","unstructured":"Hoffmann JHO, Enk AH. High-dose intravenous immunoglobulin in skin autoimmune disease. Front Immunol. 2019, 10:1090. 10.3389\/fimmu.2019.01090","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: overview and update","volume":"45","author":"Zhu YI","year":"2001","unstructured":"Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001, 45:420-434. 10.1067\/mjd.2001.114733","journal-title":"J Am Acad Dermatol"},{"key":"ref11","unstructured":"World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva. World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.\r\n. Accessed: 15 march 2020: https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2010.12.009","article-title":"Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid","volume":"40","author":"Tirado-S\u00e1nchez A","year":"2012","unstructured":"Tirado-S\u00e1nchez A, D\u00edaz-Molina V, Ponce-Olivera RM. Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid. Allergol Immunopathol. 2012, 40:152-155. 10.1016\/j.aller.2010.12.009","journal-title":"Allergol Immunopathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel G","year":"2014","unstructured":"Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014, 306:103-124. 10.1007\/s00403-013-1409-7","journal-title":"Arch Dermatol Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.62.6.827","article-title":"Anti-inflammatory action of dapsone: Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction","volume":"62","author":"Debol SM","year":"1997","unstructured":"Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997, 62:827-836. 10.1002\/jlb.62.6.827","journal-title":"J Leukoc Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling M","year":"2017","unstructured":"Sticherling M, Franke A, Aberer E, et al.. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017, 177:1299-1305. 10.1111\/bjd.15649","journal-title":"Br J Dermatol"},{"key":"ref16","article-title":"Acerca da accao das sulfamidas e das sulfonas na doenca de Duhring","volume":"8","author":"Esteves J","year":"1950","unstructured":"Esteves J, Brandao F. Acerca da accao das sulfamidas e das sulfonas na doenca de Duhring. Trab Soc Port Dermatol Venereol. 1950, 8:209-217.","journal-title":"Trab Soc Port Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142966","article-title":"Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment","volume":"89","author":"Clarindo M","year":"2014","unstructured":"Clarindo M, Possebon A, Soligo E, Uyeda H, Ruaro R, Empinotti J. Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment. An Bras Dermatol. 2014, 89:865-877. 10.1590\/abd1806-4841.20142966","journal-title":"An Bras Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S69127","article-title":"The diagnosis and treatment of dermatitis herpetiformis","volume":"8","author":"Antiga E","year":"2015","unstructured":"Antiga E, Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clin Cosmet Investig Dermatol. 2015, 8:257-265. 10.2147\/CCID.S69127","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/BF02944243","article-title":"Dermatitis herpetiformis: a review of fifty-four patients","volume":"166","author":"Egan CA","year":"1997","unstructured":"Egan CA, O\u2019loughlin S, Gormally S, Poweli FC. Dermatitis herpetiformis: a review of fifty-four patients. IJMS. 1997, 166:241-244. 10.1007\/BF02944243","journal-title":"IJMS"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/952753","article-title":"Celiac disease and dermatologic manifestations: many skin clue to unfold gluten-sensitive enteropathy","volume":"2012","author":"Caproni M","year":"2012","unstructured":"Caproni M, Bonciolini V, D\u2019Errico A, Antiga E, Fabbri P. Celiac disease and dermatologic manifestations: many skin clue to unfold gluten-sensitive enteropathy. Gastroenterol Res Pract. 2012, 2012:952753 . 10.1155\/2012\/952753","journal-title":"Gastroenterol Res Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1982.tb02489.x","article-title":"The treatment of dermatitis herpetiformis","volume":"7","author":"Fry L","year":"1982","unstructured":"Fry L. The treatment of dermatitis herpetiformis. Clin Exp Dermatol. 1982, 7:633-642. 10.1111\/j.1365-2230.1982.tb02489.x","journal-title":"Clin Exp Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000251283","article-title":"Bullous pemphigoid controlled by dapsone","volume":"152","author":"Piamphongsant T","year":"1976","unstructured":"Piamphongsant T, Ausawamongkonpan S. Bullous pemphigoid controlled by dapsone. Dermatologica. 1976, 152:352-357. 10.1159\/000251283","journal-title":"Dermatologica"},{"key":"ref23","article-title":"Dapsone for the treatment of bullous pemphigoid","volume":"1","author":"Piamphongsant T","year":"1983","unstructured":"Piamphongsant T. Dapsone for the treatment of bullous pemphigoid. Asian Pacific J Allergy Immunol. 1983, 1:19-21.","journal-title":"Asian Pacific J Allergy Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(96)80085-5","article-title":"Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases","volume":"34","author":"Bouscamt F","year":"1996","unstructured":"Bouscamt F, Chosidow O, Picard-Dahan C, et al.. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996, 34:683-684. 10.1016\/s0190-9622(96)80085-5","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1989.tb07769.x","article-title":"Dapsone as first line therapy for bullous pemphigoid","volume":"120","author":"Venning VA","year":"1989","unstructured":"Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989, 120:83-92. 10.1111\/j.1365-2133.1989.tb07769.x","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1976.tb05168.x","article-title":"Pemphigus controlled by dapsone","volume":"94","author":"Piamphongsant T","year":"1976","unstructured":"Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976, 94:681-686. 10.1111\/j.1365-2133.1976.tb05168.x","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000250907","article-title":"Dapsone in the treatment of pemphigus vulgaris","volume":"156","author":"Haim S","year":"1978","unstructured":"Haim S, Birnbaum RF. Dapsone in the treatment of pemphigus vulgaris. Dermatologica. 1978, 156:120-123. 10.1159\/000250907","journal-title":"Dermatologica"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000448028","article-title":"Efficacy of dapsone in the treatment of pemphigus vulgaris: a single-center case study","volume":"232","author":"Baum S","year":"2016","unstructured":"Baum S, Debby A, Gilboa S, Trau H, Barzilai A. Efficacy of dapsone in the treatment of pemphigus vulgaris: a single-center case study. Dermatology. 2016, 232:578-585. 10.1159\/000448028","journal-title":"Dermatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2000.00622.x","article-title":"An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers","volume":"25","author":"Tan HH","year":"2000","unstructured":"Tan HH, Tay YK. An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers. Clin Exp Dermatol. 2000, 25:224-226. 10.1046\/j.1365-2230.2000.00622.x","journal-title":"Clin Exp Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611040-00003","article-title":"Clinical pharmacokinetics of dapsone","volume":"11","author":"Zuidema J","year":"1986","unstructured":"Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986, 11:299-315. 10.2165\/00003088-198611040-00003","journal-title":"Clin Pharmacokinet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/33764-dapsone-in-the-management-of-pemphigus-and-pemphigoid-rediscovery-of-its-long-lost-efficacy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:00Z","timestamp":1707506820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/33764-dapsone-in-the-management-of-pemphigus-and-pemphigoid-rediscovery-of-its-long-lost-efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.8805","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}